Gail Berman

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

K. Mahaffey, R. Becker, R. Harrington, 2009, The Lancet.

ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

P. Libby, A. Shaunik, P. Ridker, 2022, Current Atherosclerosis Reports.

ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

P. Libby, A. Shaunik, P. Ridker, 2022, Current Atherosclerosis Reports.

Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

L. Deckelbaum, P. Ridker, S. Pocock, 2020, American heart journal.

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.

Marc P. Bonaca, E. Braunwald, D. Morrow, 2009, American heart journal.